Boston Partners
AMED

Boston Partners’s Amedisys AMED Stock Holding History

Boston Partners’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-198,827
Closed -$18.3M – 707
2024
Q1 		$18.3M Sell
198,827
-4,870
-2% -$456K 0.02% 339
2023
Q4 		$19.4M Sell
203,697
-8,004
-4% -$748K 0.03% 333
2023
Q3 		$19.7M Sell
211,701
-12,534
-6% -$1.16M 0.03% 310
2023
Q2 		$20.5M Sell
224,235
-205,004
-48% -$16.8M 0.03% 308
2023
Q1 		$32M Buy
429,239
+104,737
+32% +$9.06M 0.04% 261
2022
Q4 		$27.7M Buy
324,502
+74,553
+30% +$6.72M 0.04% 266
2022
Q3 		$24M Buy
249,949
+47,416
+23% +$5.65M 0.04% 275
2022
Q2 		$21.7M Buy
202,533
+128,588
+174% +$16.4M 0.03% 303
2022
Q1 		$12.7M Buy
73,945
+67,194
+995% +$10M 0.02% 350
2021
Q4 		$1.09M Sell
6,751
-679
-9% -$109K ﹤0.01% 521
2021
Q3 		$1.11M Buy
+7,430
New +$1.54M ﹤0.01% 512

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Boston Partners's AMED Position: Q2 2024 in Review

Boston Partners sold out of Amedisys (AMED) in Q2 2024, closing a stake of 198,827 shares — an estimated $18.3M sold.

Boston Partners first reported a position in AMED in Q3 2021 and held it in 11 quarters. The position peaked at $32M in Q1 2023. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2024.

  • Boston Partners reported no remaining Amedisys position as of Q2 2024 after selling out during the quarter.
  • Boston Partners sold 198,827 Amedisys shares in Q2 2024, an estimated $18.3M.
  • Boston Partners first reported a position in Amedisys in Q3 2021 and held it in 11 quarters.
  • Boston Partners's Amedisys position peaked at $32M in Q1 2023.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2024.

Based on Boston Partners's 13F filing for Q2 2024, filed 14 Aug 2024.